Medication info
Janumet XR Extended-Release Tablet 50/1000 mg

Janumet XR Extended-Release Tablet 50/1000 mg

Prescription medicationTabletOral
Ingredient · strength
Metformin Hydrochloride›1000mg / 1 tabletSitagliptin Phosphate Hydrate›64.25mg / 1 tablet
Manufacturer / importer
Chong Kun Dang Pharm.
Appearance
A biconvex oval film-coated tablet that is bright green with '80' engraved on one side
Packaging
28 tablets/bottle, 56 tablets/bottle
Approval status
Active

MFDS item code 201309417 · Approved 2013.09.24 · Insurance code 655501790

Summary

Main use
Improvement of glycemic control in patients with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
For antidiabetic therapy, the dose of this drug should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg. To reduce gastrointestinal adverse reactions caused by metformin, take this drug once daily with a meal, preferably in the evening, and increase the dose gradually. To maintain its extended-release properties, swallow this drug whole; do not split, crush, grind, or chew it. Take 1 tablet of this drug 100/1000 mg extended-release tablets once daily. Patients taking this drug 50/500 mg extended-release tablets or 50/1000 mg extended-release tablets should take 2 tablets together once daily. 1. Patients not currently being treated with metformin: For patients who have not previously received drug treatment for diabetes and whose blood glucose is inadequately controlled with monotherapy, or whose blood glucose cannot be adequately controlled with sitagliptin monotherapy, the initial dose of this drug is a total daily dose of sitagliptin 100 mg and metformin 1000 mg. If blood glucose is not adequately controlled with the initial dose, the dose may be gradually increased up to the maximum recommended daily dose of metformin, 2000 mg, to reduce gastrointestinal adverse reactions caused by metformin. Patients with renal impairment who are receiving a reduced dose of sitagliptin should not be switched to this drug. 2. Patients being treated with metformin: - For patients whose blood glucose is not adequately controlled with metformin monotherapy, the recommended initial dose of this drug is a total daily dose of sitagliptin 100 mg and the current metformin dose. - Patients switching from concomitant sitagliptin and metformin therapy to this drug may start at their current doses of sitagliptin and metformin. - Patients currently taking immediate-release metformin at a dose of 850 mg or 1000 mg twice daily may start this drug at 2 tablets of 50/1000 mg extended-release tablets once daily. 3. Patients whose blood glucose is not adequately controlled with metformin combined with a sulfonylurea, metformin combined with insulin, or metformin combined with a thiazolidinedione: The initial dose of this drug is a total daily dose of sitagliptin 100 mg, and the initial dose of metformin should be determined based on the patient's blood glucose level and current dose. To reduce gastrointestinal adverse reactions caused by metformin, increase the dose gradually. When administered with a sulfonylurea or insulin, consider reducing the dose of the sulfonylurea or insulin to reduce the risk of sulfonylurea- or insulin-induced hypoglycemia. Patients with renal impairment This drug may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or estimated glomerular filtration rate (eGFR) ≥ 45 and < 60 mL/min/1.73m2), who do not have other conditions that may increase the risk of lactic acidosis, with the following dose adjustment. Treatment should not be initiated with this drug because the starting dose of metformin is 500 mg or 850 mg once daily. The maximum recommended dose of metformin is 1000 mg daily. Renal function should be carefully monitored every 3-6 months. If renal function decreases to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, discontinue this drug immediately. Patients with hepatic impairment This drug should not be administered to patients with hepatic impairment because it contains metformin.

Ingredients

Importer
Chong Kun Dang Pharm.

Efficacy & effects

Improvement of glycemic control in patients with type 2 diabetes mellitus

View approved original text

This medication helps patients with type 2 diabetes in controlling their blood sugar in conjunction with diet and exercise. By combining sitagliptin and metformin, it effectively improves blood sugar levels, thereby aiding in diabetes management. Therefore, this medication is used to enhance blood sugar control in the treatment of type 2 diabetes.

How to take

Adult dose

For antidiabetic therapy, the dose of this drug should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg. To reduce gastrointestinal adverse reactions caused by metformin, take this drug once daily with a meal, preferably in the evening, and increase the dose gradually. To maintain its extended-release properties, swallow this drug whole; do not split, crush, grind, or chew it. Take 1 tablet of this drug 100/1000 mg extended-release tablets once daily. Patients taking this drug 50/500 mg extended-release tablets or 50/1000 mg extended-release tablets should take 2 tablets together once daily. 1. Patients not currently being treated with metformin: For patients who have not previously received drug treatment for diabetes and whose blood glucose is inadequately controlled with monotherapy, or whose blood glucose cannot be adequately controlled with sitagliptin monotherapy, the initial dose of this drug is a total daily dose of sitagliptin 100 mg and metformin 1000 mg. If blood glucose is not adequately controlled with the initial dose, the dose may be gradually increased up to the maximum recommended daily dose of metformin, 2000 mg, to reduce gastrointestinal adverse reactions caused by metformin. Patients with renal impairment who are receiving a reduced dose of sitagliptin should not be switched to this drug. 2. Patients being treated with metformin: - For patients whose blood glucose is not adequately controlled with metformin monotherapy, the recommended initial dose of this drug is a total daily dose of sitagliptin 100 mg and the current metformin dose. - Patients switching from concomitant sitagliptin and metformin therapy to this drug may start at their current doses of sitagliptin and metformin. - Patients currently taking immediate-release metformin at a dose of 850 mg or 1000 mg twice daily may start this drug at 2 tablets of 50/1000 mg extended-release tablets once daily. 3. Patients whose blood glucose is not adequately controlled with metformin combined with a sulfonylurea, metformin combined with insulin, or metformin combined with a thiazolidinedione: The initial dose of this drug is a total daily dose of sitagliptin 100 mg, and the initial dose of metformin should be determined based on the patient's blood glucose level and current dose. To reduce gastrointestinal adverse reactions caused by metformin, increase the dose gradually. When administered with a sulfonylurea or insulin, consider reducing the dose of the sulfonylurea or insulin to reduce the risk of sulfonylurea- or insulin-induced hypoglycemia. Patients with renal impairment This drug may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or estimated glomerular filtration rate (eGFR) ≥ 45 and < 60 mL/min/1.73m2), who do not have other conditions that may increase the risk of lactic acidosis, with the following dose adjustment. Treatment should not be initiated with this drug because the starting dose of metformin is 500 mg or 850 mg once daily. The maximum recommended dose of metformin is 1000 mg daily. Renal function should be carefully monitored every 3-6 months. If renal function decreases to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, discontinue this drug immediately. Patients with hepatic impairment This drug should not be administered to patients with hepatic impairment because it contains metformin.

Precautions

This medication contains sitagliptin and metformin, used for blood sugar control. While taking this medication, serious allergic reactions may occur; if symptoms such as rash, itching, or difficulty breathing appear, discontinue use immediately and consult a healthcare professional. Serious pancreatic inflammation, known as pancreatitis, may rarely occur, so if symptoms such as abdominal pain, nausea, vomiting, or fever occur, visit a hospital immediately. Do not take this medication if you have severely compromised kidney function, dehydration, serious infections, or heart disease. If undergoing tests using iodinated contrast agents, you must stop this medication for a certain period before and after the test, and restart only after confirming that kidney function is normal. It is safest for pregnant women, women who may become pregnant, and nursing mothers not to take this medication. This medication may cause hypoglycemia, so when skipping meals or having irregular meals, excessive exercise, or taking other glucose-lowering agents, blood sugar levels should be carefully monitored. Patients with impaired liver function or those who consume alcohol excessively may be at risk of developing lactic acidosis, a serious metabolic anomaly, hence should avoid taking this medication. Regular monitoring of kidney function and vitamin B12 levels in the blood is important to ensure they remain normal. Patients scheduled for surgery should stop taking this medication 48 hours before surgery, and only resume after recovery of oral intake and confirmation of normal kidney function. This medication has not been adequately confirmed for safety and efficacy in children, so it is advisable not to use it in pediatric patients under 18 years of age. Elderly patients may have decreased kidney function, so dose adjustments and regular kidney function monitoring are necessary when taking this medication. In case of overdose of this medication, appropriate treatment should be sought immediately from a medical facility, and since blood dialysis may be necessary, swift response is important.

Side effects

  • anaphylaxis
  • angioedema
  • Stevens-Johnson syndrome
  • acute pancreatitis
  • lactic acidosis
  • hypoglycemia
  • diarrhea
  • upper respiratory tract infection
  • headache
  • nausea
Show 17 more
  • vomiting
  • abdominal pain
  • nasopharyngitis
  • constipation
  • severe and disabling arthralgia
  • vesiculobullous pemphigoid
  • myalgia
  • limb pain
  • back pain
  • interstitial lung disease
  • pruritus
  • thrombocytopenia
  • rhabdomyolysis
  • vitamin B12 deficiency
  • rash
  • urticaria
  • cutaneous vasculitis

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in an airtight container as it is sensitive to air and moisture. The storage temperature should maintain room temperature between 1 to 30 degrees Celsius. This will help retain the medication's efficacy for an extended period.

Appearance and packaging

Appearance

A biconvex oval film-coated tablet that is bright green with '80' engraved on one side

Package unit

28 tablets/bottle, 56 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.